so if you look at it in detail
rare disease like FSGS has a higher COS from phase 2 to 3 sitting at around 50%! then phase 3 COS goes to 73%.
As i stated - 30% cos is about right for phase 2 trials like DKD however given it has already passed phase 2a i would suggest the COS for phase 2b would be higher, however i cant find any actual stats on this.
Taylor's Initiation, page-12
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
-0.010(2.86%) |
Mkt cap ! $191.0M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 35.8¢ | 33.5¢ | $1.572M | 4.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 161298 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 116726 | 8 |
View Market Depth
| Last trade - 12.17pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
34.0¢ |
Change
-0.010 ( 2.27 %) |
||||
| Open | High | Low | Volume | ||
| 35.5¢ | 36.0¢ | 33.5¢ | 3210399 | ||
| Last updated 12.28pm 07/05/2024 ? | |||||
| DXB (ASX) Chart |